This is a working overview of Cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
== Multi-chain polymerization == A monomer with functionality 3 has 3 functional groups that participate in the polymerization. This will introduce branching in a polymer and may ultimately form a cross-linked macrostructure. The point at which this three-dimensional 3D network is formed is known as the gel point, signaled by an abrupt change in viscosity. A more general functionality factor fav is defined for multi-chain polymerization, as the average number of functional groups present per monomer unit. For a system containing N0 molecules initially and equivalent numbers of two function groups A and B, the total number of functional groups is N0fav.
Though delayed a year to reach its first flight, Gemini was able to take advantage of the USSR's two-year hiatus after Voskhod, which enabled the US to catch up and surpass the previous Soviet superiority in piloted spaceflight. Gemini had ten crewed missions between March 1965 and November 1966: Gemini 3, Gemini 4, Gemini 5, Gemini 6A, Gemini 7, Gemini 8, Gemini 9A, Gemini 10, Gemini 11, and Gemini 12; and accomplished the following:
Executive: The prime minister, typically the leader of the majority rule party or coalition in the National Assembly (the lower house), serves as the country's chief executive and head of government. Responsibilities include forming a cabinet, making executive decisions, and appointing senior civil servants, subject to executive confirmation. Provincial governments: Each of the four provinces follows a similar governance system, with a directly elected Provincial Assembly choosing the Chief Minister, usually from the largest party or coalition. Chief Ministers lead the provincial cabinet and oversee provincial governance. The Chief Secretary, appointed by the prime minister, heads the provincial bureaucracy. Provincial assemblies legislate and approve the provincial budget, typically presented by the provincial finance minister annually. Ceremonial heads of provinces, the Provincial Governors, are appointed by the president based on the binding advice of the prime minister.
Sources: en.wikipedia.org
== Characteristics == Various types of kōji are used, including yellow, black, and white. The kōji is stored for two to three days at 30°C under high humidity to allow A. oryzae to grow. In this process, the starch from cereals such as wheat, buckwheat or barley as well as from sweet potato is split into glucose, creating a sweet taste. The amino acids glutamic acid and to a lesser extent also aspartic acid split off from the proteins during fermentation, resulting in a strong umami taste. Depending on the Aspergillus used, culture substrate and culture conditions (temperature, pH value, salt content, humidity), different products are created in terms of composition, flavour and odour. Kōji can be freeze-dried and crushed to produce spores. Dried kōji-spores can be stored and transported light-protected at room temperature.
=== Treatment by medical professionals === In a healthcare setting, treatment depends on the severity of symptoms and intravenous access. If a patient is conscious and able to swallow safely, food or drink may be administered, as well as glucose tabs or gel. In those with intravenous access, 25 grams of 50% dextrose is commonly administered. When there is no intravenous access, intramuscular or intra-nasal glucagon may be administered.
Peppermint was first identified in Hertfordshire, England, by a Dr. Eales, a discovery which John Ray published 1696 in the second edition of his book Synopsis Methodica Stirpium Britannicarum. He initially gave it the name Mentha spicis brevioribus et habitioribus, foliis Mentha fusca, sapore fervido piperis and later in his 1704 volume Historia Plantarum he called it Mentha palustris or Peper–Mint. The plant was then added to the London Pharmacopoeia under the name Mentha piperitis sapore in 1721. It was given the name Mentha piperita in 1753 by Carl Linnaeus in his Species Plantarum Volume 2. Linnaeus treated peppermint as a species, but it is now agreed to be a hybrid between Mentha aquatica and Mentha spicata, with M. spicata itself also being considered by some authors to be a hybrid between Mentha longifolia and Mentha suaveolens. Peppermint is a herbaceous, rhizomatous, perennial plant that grows to be 30–90 cm (12–35 in) tall, with smooth stems, square in cross section. The rhizomes are wide-spreading and fleshy, and bear fibrous roots. The leaves can be 4–9 cm (1.6–3.5 in) long and 1.5–4 cm (0.59–1.57 in) broad. They are dark green with reddish veins, with an acute apex and coarsely toothed margins. The leaves and stems are usually slightly fuzzy. The flowers are purple, 6–8 mm (0.24–0.31 in) long, with a four-lobed corolla about 5 mm (0.20 in) diameter; they are produced in whorls (verticillasters) around the stem, forming thick, blunt spikes. Flowering season lasts from mid- to late summer.
==== Dietary intervention ==== Remedies for diabetes before the mid-1800s often consisted of blends of ingredients, bloodletting, and opium (which was still being mentioned by William Osler in 1915). Another treatment that prevailed into the 20th century was to provide the patient with extra nourishment to compensate for the loss of nutrients to urine. Patients under this regimen were advised to eat as much as possible; sometimes, to eat extra large quantities of sugar. This was misguided advice that resulted in early deaths. Meanwhile, greater success at controlling diabetes was found as physicians began to notice that fasting, not overfeeding, seemed to improve the symptoms of diabetes. Dietary restriction was first reported successful by John Rollo in 1797, and later by Apollinaire Bouchardat, who observed the disappearance of glycosuria in his patients during the rationing while Paris was besieged by the Germans in 1870. A variety of sugar-free, low-carbohydrate diets (occasionally involving physical restraint of patients lacking self-discipline) became increasingly popular. Among others, Frederick Madison Allen's "starvation diet" was notoriously spartan, but was shown to extend life expectancy. Elizabeth Hughes Gossett, later among the first people to be treated with insulin, was among Allen's patients.
Sources: en.wikipedia.org
Tadalafil, sold under the brand name Cialis among others, is a medication used to treat erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. It is taken by mouth. Onset is typically within half an hour and the duration is up to 36 hours. Common side effects include headache, muscle pain, flushing, and nausea. Caution is advised in those with cardiovascular disease. Rare but serious side effects include a prolonged erection that can lead to damage to the penis, vision problems, and hearing loss. Tadalafil is not recommended in people taking nitrovasodilators such as nitroglycerin, as this may result in a serious drop in blood pressure. Tadalafil is a PDE5 inhibitor which increases blood flow to the penis. It also dilates blood vessels in the lungs, which lowers the pulmonary artery pressure. Tadalafil was approved for medical use in the United States in 2003. It is available as a generic medication. In 2022, it was the 172nd most commonly prescribed medication in the United States, with more than 3 million prescriptions.
=== Closing equity gaps === Turner co-authored a paper in 2019 summarising the findings of a retrospective cohort study of New Zealand children (born 2006–2015), which identified that hospitalisation rates for infectious diseases since 1989 had increased disproportionately for Maori and Pacific children and those who were socioeconomically most deprived, but that those children who received the pneumococcal conjugate vaccine (PVC) between 2008 and 2014, were less likely to be hospitalized. The paper concludes that the use of PVC was associated with "reductions in ethnic and socioeconomic disparities in hospitalization". Turner co-authored another report on a research study that showed foreign-born migrant children living in New Zealand had an overall lower vaccination rate than NZ-born migrant and non-migrant children. It was acknowledged that there needed to be an improvement in the way such data were gathered, highlighting the importance of having "better national surveillance and migrant-specific data related to vaccination coverage to help uncover health inequities among children living in NZ and inform immunisation policy and practice". A follow-up paper on this research highlighted that to get a better understanding of migrant health, data must be disaggregated to locate hidden trends, provide information about subsets and make vulnerable groups more visible. Much of Turner's research and writing has been on the importance of people getting accurate information about immunisation, particularly to reassure parents that vaccines were safe.
=== Invention === In 1966 (1966) Sato Foods Industries Co., Ltd. invented alcohol pulverization. Sato is a food additives and seasoning manufacturer in Aichi Prefecture in Japan. (ja:佐藤食品工業 (愛知県)) A year later, in 1967, Sato began production and sales of various kinds of "high content alcohol powder Alcock" ("高含度アルコール粉末「アルコック」"). On 15 January 1974, a practical manufacturing process for alcohol powder was patented by Sato. Sato has patented the process in 17 countries around the world. In the 1970s Sato began promoting powdered alcohol in the United States. Test sales began in 1977 under the trade name "SureShot". The product "Palcohol" was announced for future release in the U.S. in 2015. In Turkey, on November 21, 1973, a former chemist named İsmail Serin invented a powdered version of rakı, a traditional Turkish anise-flavored alcoholic beverage.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.